Last 7 days
-4.2%
Last 30 days
-10.1%
Last 90 days
-19.0%
Trailing 12 Months
-45.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-07-31 | Bhanji Muna | sold | -11,217 | 42.33 | -265 | - |
2023-07-06 | Bhanji Muna | sold | -73,373 | 39.3 | -1,867 | - |
2023-07-03 | Clark Eliana | sold | -14,583 | 40.51 | -360 | evp, chief technical officer |
2023-06-20 | Clark Eliana | acquired | 61,350 | 12.27 | 5,000 | evp, chief technical officer |
2023-06-20 | Clark Eliana | sold | -225,000 | 45.00 | -5,000 | evp, chief technical officer |
2023-06-14 | CHASE WILLIAM J | acquired | - | - | 1,673 | - |
2023-06-14 | Crowley John F | acquired | - | - | 4,425 | - |
2023-06-14 | Bhanji Muna | acquired | - | - | 4,425 | - |
2023-06-14 | GOODMAN JESSE | acquired | - | - | 4,425 | - |
2023-06-14 | Keresty Georgia | acquired | - | - | 4,425 | - |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 63.00 | 734 | -% |
2023-09-07 | Triatomic Management LP | sold off | -100 | -372,700 | - | -% |
2023-09-06 | Deep Track Capital, LP | added | 18.58 | 7,811,540 | 34,069,500 | 1.58% |
2023-09-01 | Orchard Capital Management, LLC | new | - | 6,490,340 | 6,490,340 | 2.18% |
2023-08-23 | WOLVERINE TRADING, LLC | new | - | 264,541 | 264,541 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 24.64 | 93,545 | 350,708 | -% |
2023-08-21 | VitalStone Financial, LLC | new | - | - | - | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 6.45 | 571,299 | 4,039,420 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -6.2 | 23,176 | 817,639 | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -52.63 | -18,999,900 | 20,440,100 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.28% | 7,810,226 | SC 13G/A | |
Jan 25, 2023 | blackrock inc. | 8.7% | 7,254,921 | SC 13G | |
Feb 14, 2022 | nikko asset management americas, inc. | 3.70% | 2,753,903 | SC 13G/A | |
Feb 11, 2022 | regeneron pharmaceuticals, inc. | 4.98% | 3,702,995 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 10.64% | 7,916,882 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G | |
Feb 04, 2022 | sumitomo mitsui trust holdings, inc. | 3.70% | 2,753,903 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 7.6% | 5,620,376 | SC 13G/A | |
Nov 26, 2021 | ark investment management llc | 10.40% | 7,642,452 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Aug 03, 2023 | 10-Q | Quarterly Report | |
Aug 03, 2023 | 8-K | Current Report | |
Aug 02, 2023 | 4 | Insider Trading | |
Jul 31, 2023 | 144 | Notice of Insider Sale Intent | |
Jul 10, 2023 | 4 | Insider Trading | |
Jul 06, 2023 | 144 | Notice of Insider Sale Intent | |
Jul 06, 2023 | 4 | Insider Trading | |
Jun 22, 2023 | 4 | Insider Trading | |
Jun 20, 2023 | 144 | Notice of Insider Sale Intent | |
Jun 16, 2023 | 8-K | Current Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABBV | 271.4B | 56.0B | 2.30% | 9.45% | 31.25 | 4.84 | -2.31% | -31.27% |
BGNE | 265.4B | 1.8B | -1.67% | 25.43% | -153.19 | 146.56 | 69.45% | 14.65% |
VRTX | 90.8B | 9.5B | 0.45% | 22.78% | 26.99 | 9.56 | 13.83% | 5.33% |
REGN | 89.0B | 12.7B | -1.51% | 18.09% | 20.7 | 7.02 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -7.00% | -17.21% | -20.61 | 17.72 | 39.94% | -8.44% |
SRPT | 11.0B | 1.0B | 3.70% | 3.57% | -12.12 | 10.97 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.05 | 4.98 | 18.01% | 38.16% |
MID-CAP | ||||||||
BPMC | 3.1B | 225.6M | 0.04% | -28.00% | -5.53 | 13.59 | -2.11% | 21.02% |
MDGL | 3.0B | - | -10.01% | 147.80% | -9.03 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.59 | 6.42 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -14.18% | -57.07% | -2.57 | 69.63 | - | -14.43% |
SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.23 | 4.28 | 77.72% | 112.02% |
MGNX | 281.2M | 152.5M | -11.67% | 38.41% | 37.75 | 1.84 | 127.84% | 103.41% |
CRBP | 29.9M | - | 1.35% | 3552.08% | -0.65 | - | - | -31.51% |
8.9%
4.9%
13.1%
100%
95%
71.5%
Y-axis is the maximum loss one would have experienced if Intellia Therapeutics was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | -0.8% | 53,039,000 | 53,475,000 | 52,121,000 | 51,402,000 | 45,340,000 | 37,860,000 | 33,053,000 | 26,794,000 | 41,810,000 | 51,523,000 | 57,994,000 | 62,335,000 | 50,731,000 | 45,586,000 | 43,103,000 | 40,047,000 | 36,839,000 | 33,398,000 | 30,434,000 | 29,222,000 | 29,131,000 |
S&GA Expenses | 8.9% | 103,871,000 | 95,351,000 | 90,306,000 | 88,788,000 | 85,354,000 | 79,905,000 | 71,096,000 | 59,751,000 | 51,606,000 | 46,449,000 | 44,169,000 | 42,382,000 | 40,247,000 | 41,839,000 | 41,058,000 | 40,790,000 | 40,629,000 | 35,316,000 | 32,189,000 | 33,694,000 | 31,135,000 |
R&D Expenses | 6.5% | 409,077,000 | 384,000,000 | 419,979,000 | 391,106,000 | 354,941,000 | 323,626,000 | 229,807,000 | 196,877,000 | 176,147,000 | 155,034,000 | 150,408,000 | 143,908,000 | 131,665,000 | 119,354,000 | 108,413,000 | 96,600,000 | 92,324,000 | 90,331,000 | 89,115,000 | 90,367,000 | 84,611,000 |
EBITDA | - | - | - | - | - | - | - | -60,652,000 | -60,941,000 | -61,125,000 | -61,193,000 | -61,243,000 | -61,255,000 | -61,474,000 | -61,701,000 | -61,943,000 | -62,295,000 | -62,526,000 | -62,792,000 | - | - | - |
EBITDA Margin | - | - | - | - | - | - | - | -1.83 | -2.27 | -1.46 | -1.19 | -1.06 | -0.98 | -1.21 | -1.35 | -1.44 | -1.56 | -1.70 | -1.88 | - | - | - |
EBT Margin | - | - | - | - | - | - | - | -2.04 | -2.52 | -1.62 | -1.31 | -1.16 | -1.08 | -1.33 | -1.48 | -1.57 | -1.69 | -1.83 | -2.02 | - | - | - |
Net Income | -5.3% | -453,443,000 | -430,440,000 | -474,186,000 | -442,016,000 | -400,431,000 | -368,559,000 | -267,892,000 | -228,847,000 | -185,043,000 | -148,630,000 | -134,231,000 | -120,315,000 | -116,109,000 | -109,399,000 | -99,533,000 | -90,323,000 | -89,391,000 | -85,927,000 | -85,343,000 | -90,240,000 | -82,894,000 |
Net Income Margin | 100.0% | - | -8.05 | -9.10 | -8.60 | -8.83 | -9.73 | -8.10 | -8.54 | -4.43 | -2.88 | -2.31 | -1.93 | -2.29 | -2.40 | -2.31 | - | - | - | - | - | - |
Free Cashflow | 100.0% | - | -378,775,000 | -346,845,000 | -310,583,000 | -297,380,000 | -264,228,000 | -237,786,000 | -221,499,000 | -181,195,000 | -68,895,000 | -53,497,000 | -43,499,000 | -41,439,000 | -126,438,000 | -110,034,000 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | -6.7% | 1,323 | 1,418 | 1,520 | 1,084 | 1,110 | 1,203 | 1,294 | 1,335 | 672 | 717 | 676 | 459 | 491 | 315 | 334 | 347 | 352 | 344 | 347 | 321 | 340 |
Current Assets | -2.5% | 940 | 964 | 1,217 | 859 | 895 | 875 | 769 | 815 | 549 | 601 | 617 | 416 | 446 | 270 | 289 | 296 | 307 | 304 | 325 | 299 | 318 |
Cash Equivalents | -41.6% | 172 | 294 | 524 | 141 | 148 | 133 | 123 | 335 | 130 | 142 | 160 | 180 | 362 | 81.00 | 57.00 | 38.00 | 49.00 | 47.00 | 59.00 | 293 | 306 |
Net PPE | 5.0% | 33.00 | 32.00 | 28.00 | 27.00 | 26.00 | 24.00 | 21.00 | 20.00 | 19.00 | 16.00 | 16.00 | 16.00 | 16.00 | 17.00 | 18.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 |
Current Liabilities | -3.4% | 100 | 103 | 127 | 131 | 124 | 126 | 126 | 98.00 | 74.00 | 61.00 | 64.00 | 56.00 | 59.00 | 35.00 | 36.00 | 38.00 | 38.00 | 39.00 | 41.00 | 26.00 | 25.00 |
Shareholder's Equity | -7.2% | 1,105 | 1,191 | 1,236 | 825 | 881 | 954 | 1,040 | 1,107 | 495 | 546 | 527 | 330 | 352 | 248 | 270 | 276 | 277 | 264 | 278 | 263 | 279 |
Retained Earnings | -9.7% | -1,403 | -1,280 | -1,177 | -1,063 | -950 | -849 | -703 | -621 | -550 | -481 | -435 | -392 | -365 | -332 | -300 | -272 | -248 | -223 | -201 | -181 | -159 |
Additional Paid-In Capital | 1.6% | 2,513 | 2,474 | 2,420 | 1,898 | 1,841 | 1,812 | 1,746 | 1,729 | 1,045 | 1,027 | 962 | 723 | 717 | 580 | 570 | 548 | 526 | 488 | 479 | 445 | 439 |
Shares Outstanding | 0.3% | 88.00 | 88.00 | 87.00 | 77.00 | 76.00 | 75.00 | 74.00 | 74.00 | 68.00 | 67.00 | 66.00 | 54.00 | 52.00 | 50.00 | 50.00 | 49.00 | 46.00 | 45.00 | 43.00 | 43.00 | 43.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | -1.4% | -368 | -362 | -333 | -298 | -284 | -252 | -225 | -210 | -174 | -63.74 | -49.91 | -38.35 | -35.24 | -120 | -103 | -83.12 | -70.12 | -64.94 | -61.26 | -74.03 | -78.46 |
Share Based Compensation | 13.3% | 113 | 100 | 91.00 | 81.00 | 72.00 | 59.00 | 47.00 | 38.00 | 28.00 | 22.00 | 20.00 | 17.00 | 15.00 | 15.00 | 15.00 | 16.00 | 17.00 | 18.00 | 17.00 | 20.00 | 19.00 |
Cashflow From Investing | -1380.0% | -139 | -9.41 | 160 | 31.00 | -415 | -477 | -550 | -602 | -357 | -297 | -214 | 24.00 | 147 | 77.00 | 25.00 | -258 | -229 | -253 | -260 | -7.16 | -7.41 |
Cashflow From Financing | -0.6% | 534 | 538 | 583 | 79.00 | 724 | 725 | 737 | 969 | 300 | 426 | 372 | 157 | 203 | 77.00 | 76.00 | 87.00 | 43.00 | 37.00 | 40.00 | 152 | 150 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Income Statement [Abstract] | ||||
Collaboration revenue | $ 13,594 | $ 14,030 | $ 26,200 | $ 25,282 |
Type of Revenue [Extensible List] | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |
Operating expenses: | ||||
Research and development | $ 115,276 | $ 90,199 | $ 212,392 | $ 223,294 |
General and administrative | 30,652 | 22,132 | 58,100 | 44,535 |
Total operating expenses | 145,928 | 112,331 | 270,492 | 267,829 |
Operating loss | (132,334) | (98,301) | (244,292) | (242,547) |
Other income (expense), net: | ||||
Interest income | 12,653 | 703 | 24,633 | 1,243 |
Loss from equity method investment | (4,000) | (3,252) | (7,048) | (5,997) |
Change in fair value of contingent consideration | 0 | 172 | (100) | (249) |
Total other income (expense), net | 8,653 | (2,377) | 17,485 | (5,003) |
Net loss | $ (123,681) | $ (100,678) | $ (226,807) | $ (247,550) |
Net loss per share, basic | $ (1.4) | $ (1.33) | $ (2.58) | $ (3.29) |
Net loss per share, diluted | $ (1.4) | $ (1.33) | $ (2.58) | $ (3.29) |
Weighted average shares outstanding, basic | 88,185 | 75,823 | 87,979 | 75,282 |
Weighted average shares outstanding, diluted | 88,185 | 75,823 | 87,979 | 75,282 |
Other comprehensive loss: | ||||
Unrealized (loss) gain on marketable securities | $ (1,482) | $ (932) | $ 1,507 | $ (6,060) |
Other comprehensive gain (loss) from equity method investment | 292 | (560) | 2,086 | (862) |
Comprehensive loss | $ (124,871) | $ (102,170) | $ (223,214) | $ (254,472) |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 171,806 | $ 523,506 |
Marketable securities | 736,268 | 669,116 |
Accounts receivable ($0 and $0.3 million, respectively, from related party) | 5,056 | 3,768 |
Prepaid expenses and other current assets | 26,485 | 20,407 |
Total current assets | 939,615 | 1,216,797 |
Marketable securities - noncurrent | 164,013 | 69,338 |
Property and equipment, net | 33,194 | 27,921 |
Operating lease right-of-use assets | 123,550 | 133,076 |
Equity method investment | 21,837 | 32,455 |
Investments and other assets | 41,031 | 40,527 |
Total Assets | 1,323,240 | 1,520,114 |
Current Liabilities: | ||
Accounts payable | 11,634 | 5,154 |
Accrued expenses ($1.4 million and $1.6 million, respectively, from related party) | 49,534 | 60,876 |
Current portion of operating lease liability | 16,750 | 16,685 |
Current portion of deferred revenue ($2.9 million and $19.9 million, respectively, from related party) | 21,933 | 43,839 |
Total current liabilities | 99,851 | 126,554 |
Deferred revenue, net of current portion | 12,919 | 19,932 |
Long-term operating lease liability | 105,582 | 114,018 |
Contingent consideration liability | 0 | 24,026 |
Commitments and contingencies (Note 6) | ||
Stockholders’ Equity: | ||
Common stock, $0.0001 par value; 240,000,000 and 120,000,000 shares authorized at June 30, 2023 and December 31, 2022, respectively; 88,347,634 and 87,103,007 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 9 | 9 |
Additional paid-in capital | 2,512,741 | 2,420,223 |
Accumulated other comprehensive loss | (3,868) | (7,461) |
Accumulated deficit | (1,403,994) | (1,177,187) |
Total stockholders’ equity | 1,104,888 | 1,235,584 |
Total Liabilities and Stockholders’ Equity | $ 1,323,240 | $ 1,520,114 |